Table 1.

Summary of studies that found predictors of HCC development after DAA exposure.

Study	Predictors for occurrence	Predictors for recurrence
Conti et al. [12]	Liver cirrhosis, Child stage B, Thrombocytopenia	Increased age, liver stiffness score
Cabibbo et al. [38]	N/A	Previous HCC recurrence, baseline tumor size
Minami et al. [18]	N/A	Alpha-fetoprotein -L3, DCP, number of previous HCC managements, Time elapsed between last HCC treatment and DAA start
Kanwal et al. [29]	Liver cirrhosis, alcohol use
Ogawa et al. [37]	N/A	Liver cirrhosis, Time between HCC management and DAA treatment less than one year, Palliative HCC treatment [TACE, radiotherapy
Ikeda et al. [49]	N/A	Multiple HCC treatment sessions, Alpha-fetoprotein level, Prothrombin time
Mettke et al. [48]	MELD score, Alpha-fetoprotein level
Kolly et al. [20]	N/A	Time between HCC treatment and starting DAA therapy
Nagata et al. [23]	N/A	Alpha-fetoprotein, WFA-M2BP level
Calvaruso et al. [30]	Hypoalbuminemia, absence of SVR, thrombocytopenia
Shimizu et al. [21]	N/A	HBcAb positivity, TACE
Mashiba et al. [50]	N/A	Alpha-fetoprotein level, SVR, baseline BCLC stage of HCC